Anal Carcinoma - Onco'Zine

Anal Cancer

A detailed Overview for Clinicians.

General Explanation

Anal cancer is a rare malignancy, representing less than 1% of all cancers, but its incidence is rising, especially among women and older adults. The predominant histological subtype is squamous cell carcinoma (SCC, ~80–85%), most often arising in the anal canal’s squamocolumnar transition zone. The etiology is strongly linked to persistent infection with high-risk HPV (types 16 and 18), accounting for 80–90% of cases. Other types include adenocarcinoma, melanoma, and neuroendocrine tumors.

Epidemiology

Approximately 10,000 new cases per year in the US; incidence is higher in women (F:M ratio ≈2:1).
Peak incidence is between ages 60–84.
Incidence is increasing, particularly in high-risk demographics such as people living with HIV and men who have sex with men.

Risk Factors

HPV infection: Most significant factor, especially persistent high-risk types (HPV 16/18).
Immunosuppression: HIV infection (40-fold increased risk), organ transplant recipients, chronic corticosteroid or immunosuppressive drug use.
Sexual behavior: Multiple lifetime sexual partners, receptive anal intercourse, early sexual debut, MSM.
History of HPV-related neoplasia: Previous cervical, vulvar, or vaginal cancer or intraepithelial neoplasia.
Smoking: Independent risk, impairs immune surveillance and epithelial repair.
Older age and Female sex: Higher rates with advancing age and in females.
Other: Chronic local inflammation, autoimmune disease, previous radiotherapy.

Clinical Presentation

Early-stage disease may be asymptomatic.
Most common presenting symptoms:
- Rectal bleeding: Present in up to 50%, often mistaken for hemorrhoids.
- Anal/perianal pain or pressure
- Palpable mass or growth: Detected on DRE or seen externally.
- Pruritus or mucopurulent discharge
- Tenesmus, change in stool caliber, fecal incontinence, or bowel habit change
- Advanced disease: Rectovaginal fistula, obstructive symptoms, inguinal lymphadenopathy

Diagnosis and Workup

History & Physical: Assess for risk factors, symptom duration, and progression.
Exam: Inspection, DRE, palpation of inguinal and femoral lymph nodes, gynecologic exam in women.
Anoscopy with biopsy: Histologic confirmation is mandatory.
Imaging for staging:
- MRI pelvis: Preferred for T and N staging, assesses sphincter invasion.
- CT chest/abdomen/pelvis: For distant metastasis.
- PET-CT: For equivocal lesions, suspected metastasis, or post-treatment surveillance.
- Endoanal ultrasound: High sensitivity for T1–T2, but operator dependent.
- Inguinal node ultrasound with FNA: For suspicious lymphadenopathy.
Laboratory: CBC, LFTs, HIV status, p16 (surrogate for HPV), consider HPV DNA testing.
Screening: Anal cytology/anal Pap and high-resolution anoscopy in high-risk patients (e.g., HIV+, history of AIN).

Staging (AJCC 9th Edition)

Primary tumor (T):
- Tis: Carcinoma in situ/HSIL/AIN 2–3
- T1: ≤2 cm
- T2: >2 cm, ≤5 cm
- T3: >5 cm
- T4: Any size, invades adjacent organs (vagina, bladder, urethra)
Regional nodes (N): Inguinal, mesorectal, internal/external iliac nodes
Metastasis (M): Distant organs (liver, lungs)
Stage groupings: 0 (in situ) to IV (any T/N, M1)

Treatment Options

Localized SCC (anal canal):
- Chemoradiotherapy (CRT): 5-FU + mitomycin C + RT (Nigro regimen) is the standard. Capecitabine may substitute for 5-FU.
- Local excision: For select, small (T1N0) well-differentiated perianal or margin tumors.
- Radiation techniques: IMRT preferred for minimizing toxicity.
- Follow-up: Tumor response may take up to 6 months; biopsies are indicated for persistent disease.
Persistent or Recurrent Disease: Salvage abdominoperineal resection (APR) with permanent colostomy.
Metastatic Disease: Systemic chemotherapy (carboplatin/paclitaxel preferred), consideration of immunotherapy (PD-1 inhibitors like nivolumab (Opdivo®; Bristol-Myers Squibb) or pembrolizumab (Keytruda®; Merck & Co/MSD) for refractory cases, and metastasectomy for select patients.
HIV-positive patients: May require dose adjustments due to increased toxicity.

Prevention & Screening

HPV vaccination: Strongly recommended, especially for high-risk groups, proven to reduce incidence of AIN and anal cancer.
Routine screening: Anal cytology and high-resolution anoscopy for HIV+ individuals and those with prior HPV-related neoplasia.

Prognosis, Complications, and Outlook

Prognosis:
- 5-year overall survival (OS): ~80% (localized), 60% (regional nodes), 30% (distant metastasis)
- Main determinants: Tumor size, nodal involvement, presence of metastasis, response to CRT
Complications: Acute (dermatitis, proctitis, neutropenia, mucositis) and chronic (anal stenosis, necrosis, sexual/urinary dysfunction, incontinence)
Quality of life: May be affected by side effects, but many acute toxicities resolve within 3 months post-therapy
Health-related Quality of Life (hrQoL): Regular follow-up with DRE, imaging, and anoscopy is critical, as most recurrences occur within 2 years of treatment.
Multidisciplinary care: Coordination among oncologists, surgeons, radiologists, nurses, and pharmacists optimizes outcomes and minimizes complications.

Highlights of Prescribing Information

Nivolumab (Opdivo®; Bristol-Myers Squibb)[Prescribing Information]
Pembrolizumab (Keytruda®; Merck & Co/MSD)[Prescribing Information]
Reference

A Guide for Patients

What is Anal Cancer?

Anal cancer is an uncommon type of cancer that begins in the tissues of your anus—the opening at the end of your digestive tract where stool leaves your body. Most anal cancers are linked to a virus called HPV (human papillomavirus), which can also cause other types of cancer, like cervical cancer.

Who Gets Anal Cancer?

Anyone can get anal cancer, but you might be more at risk if you:

Have HPV infection (a common virus spread through skin-to-skin or sexual contact)
Have a weakened immune system (for example, if you have HIV or take medicines that lower your immunity)
Smoke cigarettes
Have had many sexual partners or engage in anal sex
Have had other HPV-related cancers like cervical, vaginal, or vulvar cancer
Are older (most people diagnosed are over 60)

What Symptoms Should I Watch For?

Bleeding from the anus (can look like blood on toilet paper or in the stool)—often mistaken for hemorrhoids
Pain, pressure, or feeling a lump near the anus
Itching or unusual discharge (like pus or mucus)
Changes in your bowel habits (such as narrower stools, incontinence, or needing to use the bathroom more urgently or often)
Some people have no symptoms at first, so it’s important to tell your doctor about any changes.

How Do Doctors Find Out if I Have Anal Cancer?

Ask about your symptoms and medical history
Physical exam: The doctor will look at and feel the anal area (with a gloved finger)
Anoscopy: A small tube with a light lets the doctor see inside the anus
Biopsy: If the doctor finds something unusual, they’ll take a small sample (biopsy) to check for cancer cells
Imaging tests: You might have MRI, CT, or PET scans to see if the cancer has spread
Testing for infections: You may be tested for HIV or HPV

How is Anal Cancer Treated?

Chemoradiation is the main treatment for most people. This means you get both radiation therapy (using high-energy rays to kill cancer cells) and chemotherapy (medicine to attack the cancer) at the same time.
Surgery is usually only needed for small cancers or if the cancer comes back after other treatment.
Advanced cancer: If the cancer has spread to other parts of the body, you might need more chemotherapy, radiation, or new treatments like immunotherapy (which helps your immune system fight cancer).
Most people DO NOT need to have their anus removed or need a permanent colostomy bag.

What are the Stages of Anal Cancer?

Staging describes how much cancer is in your body:

Stage 0: Very early cancer or “pre-cancer”
Stages I–III: Cancer is only in the anus or nearby areas
Stage IV: Cancer has spread to other parts of the body

What is the Outlook for People with Anal Cancer?

When found early, anal cancer is very treatable and often curable.
Most people (8 out of 10) with early-stage disease are alive 5 years after diagnosis.
If cancer has spread to lymph nodes or distant organs, it’s harder to treat, but new therapies are improving results.
Side effects from treatment (like skin problems, pain, or changes in bowel habits) are common but often improve after treatment ends.
Long-term follow-up is important to check for recurrence and manage any side effects.

Can Anal Cancer Be Prevented?

HPV vaccination is very effective at preventing the types of HPV that cause most anal cancers. Ask your doctor if you or your children should get the vaccine.
Safe sex practices (using condoms and limiting the number of sexual partners) can help reduce risk.
Don’t smoke—quitting reduces your risk.
If you’re at higher risk (for example, living with HIV), regular check-ups and screening tests can help find problems early.

What Should I Do if I Have Symptoms?

If you have bleeding, pain, lumps, or any changes around your anus, see your doctor. Most of the time, these symptoms are not due to cancer, but only a doctor can tell for sure. Early diagnosis means better treatment and a higher chance of cure.

Disclaimer: The information provided on this website is for educational and general informational purposes only. It is not intended to be, nor does it serve as, a substitute for professional medical advice, diagnosis, or treatment. If you have questions regarding a health condition, always seek the advice of a qualified healthcare professional. Never delay seeking or disregard professional medical advice because of something you have read here.

Onco'Zine